Skip to main content
Top

CNS Drugs

1997 - 2026
Volumes
369
Issues
Chevron right icon
Issue 3/2026
Latest issue

CNS Drugs OnlineFirst articles

About this journal

CNS Drugs provides researchers and healthcare professionals with essential information on the most important aspects of drug therapies used for the management of neurological and psychiatric disorders.

Via a program of reviews and original research articles, the journal addresses major issues relating to drug therapy of these disorders, including the pharmacology, efficacy and adverse effects of the major classes of drugs; information on newly developed drugs and drug classes; the therapeutic implications of latest research into the aetiology of neurological and psychiatric disorders; and the practical management of specific clinical situations.

As a hybrid journal, CNS Drugs does not charge authors to publish using the traditional subscription-based publishing route, but does offer the option to publish accepted articles open access if authors so wish or if their funders require. This is achieved via the Springer Open Choice™ initiative. More information about this optional route to open access and the associated article processing charge can be found by clicking on the ‘How to publish with us, including Open Access’ link below.

CNS Drugs offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.

Title
CNS Drugs
Coverage
Volume 7/1997 - Volume 40/2026
Publisher
Springer International Publishing
Electronic ISSN
1179-1934
Print ISSN
1172-7047
Journal ID
40263
DOI
https://doi.org/10.1007/40263.1179-1934

Mini masterclass: enhancing outcomes in LGS (Link opens in a new window)

1.5 AMA PRA Category 1 Credit(s)

These six bite-sized videos will equip you with insights into the pathophysiological processes underlying Lennox–Gastaut syndrome, the burden on patients and caregivers, and opportunities to increase diagnostic accuracy and optimize treatment strategies.

Independent Medical Education Grant:
  • Jazz Pharmaceuticals
Watch now TODO (Link opens in a new window)

Keynote webinar | Spotlight on functional neurological disorder

FND perplexes and frustrates patients and physicians alike. Limited knowledge and insufficient awareness delays diagnosis and treatment, and many patients feel misunderstood and stigmatized. How can you recognize FND and what are the treatment options?

Prof. Mark Edwards
Watch now
Video
Image Credits
Enchancing Lennox-Gastaut Syndrome program image/© Springer Health+ IME, Human brain illustration/© (M) CHRISTOPH BURGSTEDT / SCIENCE PHOTO LIBRARY / Getty Images